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We read with interest the paper by Squintani et al. on the
association between progressive multifocal leukoencephalopathy
(PML) and Good’s syndrome (GS), which is a combined immuno-
deﬁciency syndrome occurring in thymoma.1,2
This exceptional association was described, but not formerly
reported as GS, byMalas andWeiss and in one of the case records of
the Massachusetts General Hospital; moreover Gedizlioglu et al.
and Dawson described two PML cases that are likely to have
developed in GS, although pathological examinations of the
thymus were lacking.3–6 We would like to add another case – a
patient admitted to our department.
A 58-year-old male patient presented with progressive
behavioral changes, confusion, and right hemiparesis ﬁve
months after subtotal resection of an invasive thymoma. In
the previous months the patient had suffered from herpes zoster
virus reactivation, Staphylococcus aureus pneumonia, and cuta-
neous mycoses. Bilateral asymmetric extensive hyperintense
lesions in the white matter with faint enhancement were
detected by magnetic resonance imaging (MRI); cerebrospinal
ﬂuid (CSF) showed the presence of JC virus (JCV) DNA (810
copies/ml). Blood analyses revealed reduction of IgM (31 g/dl;
normal value 40–300 g/dl), reversal of CD4/CD8 ratio (0.6;
normal value 0.8–2.4), and impaired cytokine production after
phytohemagglutinin stimulation. The diagnosis of PML in GS
was established. On the basis of previous reports, cidofovir,Figure 1.MRI of PML lesion after cidofovir and intravenous immunoglobulin treatment: (
post-contrast T1-weighted sequence demonstrating contrast enhancement typical of IR
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tered.7,8 Four months after the diagnosis, the patient showed
slight worsening of cognitive functions; MRI revealed increased
enhancement and the presence of edema; three subsequent
CSF analyses demonstrated a progressive decrease to undetect-
able JCV DNA and the immunological functions improved. All
these ﬁndings suggested a possible immune reconstitution
inﬂammatory syndrome (IRIS), and intravenous steroids were
added (Figure 1).9 At this time, 11 months after diagnosis, the
patient is alive and in stable condition with reduced MRI
enhancement.
In the six cases of PML in GS reported, a variable pattern of
immunodeﬁciency has been described or suggested: the patient
presented by Squintani et al. deﬁnitely did not reveal a T-cell
defect, while our patient demonstrated both immune humoral
and cellular impairment. In addition, a B-cell defect, as in the case
of Squintani et al., can induce impairment of the T-cell
compartment, as suggested by the occurrence of opportunistic
infections.10
As the prognosis of PML in GS is very poor, the risk of rare
opportunistic infections of the central nervous system in thymoma
should be considered whenever behavioral, cognitive, and/or
motor deﬁcits occur. An integrated treatment with potentially
active antiviral drugs and attempts to restore immune function by
immunoglobulin replacement should be considered in order to
achieve prolonged survival and disappearance of JCV in the CSF, as
in our case.A) axial-FLAIR sequence demonstrating diffuse subcortical hyperintense lesions; (B)
IS.
ses. Published by Elsevier Ltd. All rights reserved.
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